Fertility and Sterility
Volume 93, Issue 2 , Pages 374-378 , 15 January 2010

Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program

Presented at the 23rd Annual Meeting of the European Society of Human Reproduction and Embryology, Lyon, France, July 3, 2007.

  • Teresa M. Erb, M.D.

      Affiliations

    • Reproductive Endocrinology and Infertility, Magee Women's Hospital, Pittsburgh, Pennsylvania
    • ,
  • Wendy Vitek, M.D.

      Affiliations

    • Obstetrics and Gynecology, Magee Women's Hospital, Pittsburgh, Pennsylvania
    • ,
  • Anthony N.G. Wakim, M.D.

      Affiliations

    • Reproductive Endocrinology and Infertility, Magee Women's Hospital, Pittsburgh, Pennsylvania
    • Corresponding Author InformationReprint requests: Anthony N. G. Wakim, M.D., Magee Women's Hospital, 300 Halket Street, Pittsburgh, PA 15213 (FAX: 412-641-7453).

Received 6 June 2008 ,Revised 4 November 2008 ,Accepted 10 December 2008.

References 

  1. Brodi D, Vernaeve V, Guillen JJ, Vidal R, Figueras F, Coll O. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum Reprod. 2006;21:2246–2251
  2. Prapas N, Prapas Y, Panagiotidis Y, Vanderzwalmen , Schoysman R, Makedos G. GnRH agonist versus GnRH antagonists in oocyte donation cycles: a prospective randomized study. Hum Reprod. 2005;20:1516–1520
  3. Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883–895
  4. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonist in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Arch Gynecol Obstet. 2001;265:175–182
  5. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonist does not compromise embryo implantation rates. Fertil Steril. 2006;76:1682–1687
  6. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159–168
  7. Huisman G, Fauser B, Eijkemans M, Pieters M. Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. Fertil Steril. 2000;73:117–122
  8. Veeck LL. An atlas of human gametes and conceptuses. New York: Parthenon; 1998;40–45
  9. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies prevention and treatment. Fertil Steril. 1992;58:249–261
  10. Soares SR, Velasco JAG, Fernandez M, Bosh E, Remohi J, Pellicer A, et al. Clinical factors affecting endometrial receptiveness in oocyte donor cycles. Fertil Steril. 2008;89:491–501
  11. Griesinger G, Kolibianakis E, Papanikolaou E, Diedrich K, Van Steirteghem A, Devroey P, et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril. 2007;88:616–621

 T.E. has nothing to disclose. W.V. has nothing to disclose. A.W. has nothing to disclose.

PII: S0015-0282(08)04681-5

doi: 10.1016/j.fertnstert.2008.12.015

Fertility and Sterility
Volume 93, Issue 2 , Pages 374-378 , 15 January 2010

Article Tools

* Image Usage & Resolution